United Therapeutics Corporation (UTHR) Share Price Today, Stock Analysis, Annual Report | Value Research United Therapeutics Corporation (UTHR) - Get live share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial report.

United Therapeutics Corporation (UTHR)

Download Stock Report

NASDAQ: UTHR

  • Price Change
  • Market Capitalisation market-capitalisation-info $10,178 Mln

  • 12 Month Earnings monthly-earning $728 Mln
  • Price to Earnings price-to-earning 14.14

United Therapeutics Corporation (UTHR) Share Price

$225.87

As on 29-Sep-2023 16:00 EDT

up-down-arrow $-0.16-0.07%

  • Prev Close info

    $226.03

  • Day's Openinfo

    $227.13

  • Today's Highinfo

    $227.76

  • Today's Lowinfo

    $224.78

  • Today's Volumeinfo

    305,527

Please wait...

United Therapeutics Corporation (UTHR) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
United Therapeutics (UTHR)
-18.78 -2.42 5.15 7.01 30.55 12.05 11.12
S&P BSE Sensex
8.20 1.28 2.99 16.31 20.12 12.69 12.81
#
-- -- -- -- -- -- --
As on 29-Sep-2023  |  #As on
2022
2021
2020
2019
2018
2017
2016
United Therapeutics (UTHR)
28.70 42.35 72.33 -19.12 -26.27 3.15 -8.42
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

United Therapeutics Corporation (UTHR) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of United Therapeutics Corporation (UTHR)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Founder, Chairman & CEO

        Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.

        Pres & COO

        Mr. Michael I. Benkowitz

        Headquarters

        Silver Spring, MD

        FAQs for United Therapeutics Corporation (UTHR)

        The total asset value of United Therapeutics Corporation (UTHR) stood at $ 6,671 Mln as on 31-Mar-23

        The share price of United Therapeutics Corporation (UTHR) is $225.870000 (NASDAQ) as of 29-Sep-2023 16:00 EDT. United Therapeutics Corporation (UTHR) has given a return of 30.55% in the last 3 years.

        United Therapeutics Corporation (UTHR) has a market capitalisation of $ 10,178 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of United Therapeutics Corporation (UTHR) is 2.80 times as on 02-Jun-2023, a 0.1% premium to its peers’ median range of 2.54 times.

        The P/E (price to earnings) ratio of United Therapeutics Corporation (UTHR) is 14.14 times as on 02-Jun-2023.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the United Therapeutics Corporation (UTHR) and enter the required number of quantities and click on buy to purchase the shares of United Therapeutics Corporation (UTHR).

        United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

        The CEO & director of Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.. is United Therapeutics Corporation (UTHR), and CFO & Sr. VP is Mr. Michael I. Benkowitz.

        The promoters of United Therapeutics Corporation (UTHR) have pledged 0% of the total equity as on Mar-23.

        United Therapeutics Corporation (UTHR) Ratios
        Return on equity(%)
        15.04
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.16
        Dividend yield(%)
        0

        Yes, TTM profit after tax of United Therapeutics Corporation (UTHR) was $728 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $10,177.73 Mln
        • Revenue (TTM)revenue-information $1,981.30 Mln
        • Earnings (TTM) earning-information $728.30 Mln
        • Cash date-information $2,863.40 Mln
        • Total Debt info $800.00 Mln
        • Insider's Holding 1.76%
        • Liquidity liquidity High
        • 52 Week range week-range $204.44 - 283.09
        • Shares outstanding share-outstanding 46,854,500
        • 10 Years Aggregate:

          CFO: $5,009.29 Mln

          EBITDA: $6,849.43 Mln

          Net Profit: $4,500.47 Mln

        About The Company

        • IPO Date 17-Jun-1999
        • Founder, Chairman & CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
        • Pres & COO Mr. Michael I. Benkowitz
        • Listing key-listing NASDAQ: UTHR
        • Country United States
        • Headquarters headquarters Silver Spring, MD
        • Website website https://www.unither.com
        • Business

          United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally....  Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon